NLRP3 and systemic sclerosis: Other small molecule NLRP3 inhibitors under investigation include IFM2427, inzomelid, somalix, IZD334, and NT-0167 (El-Sharkawy et al., 2020; Chen et al., 2021); their relevance and benefit to SSc-ILD will require additional translational and clinical evaluation.